Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069772 | 0.94 | MAPT (0.56) | MAPTRAB9ANPC1TP53KDM4E | |
| SCHEMBL10563073 | 0.89 | MAPT (0.66) | MAPTRAB9ANPC1TP53KDM4E | |
| SCHEMBL12055335 | 0.88 | MAPT (0.60) | MAPTRAB9ANPC1TP53KDM4E | |
| SCHEMBL330103 | 0.85 | BCHE (0.57) | MAPTRAB9ANPC1TP53KDM4E | |
| SCHEMBL2070701 | 0.84 | ALDH1A1 (0.69) | MAPTRAB9ANPC1TP53KDM4E | |
| SCHEMBL10077375 | 0.83 | MAPT (0.56) | MAPTRAB9ANPC1TP53KDM4E | |
| SCHEMBL2069803 | 0.82 | BCHE (0.54) | MAPTRAB9ANPC1TP53KDM4E | |
| SCHEMBL30130271 | 0.82 | ALOX15 (0.58) | MAPTRAB9ANPC1KDM4EALDH1A1 | |
| SCHEMBL28730377 | 0.82 | MAPT (0.63) | MAPTRAB9ANPC1TP53KDM4E | |
| SCHEMBL28857737 | 0.82 | ALOX15 (0.58) | MAPTRAB9ANPC1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2016-10-06 | — | — | US | disclosed |
| US-9381186-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2015-12-10 | — | — | US | disclosed |
| US-9138478-B2 | Substituted chroman derivatives, medicaments and use in therapy | MEI PHARMA, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2407462-B1 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MEI PHARMA, INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-8697891-B2 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2407462-A1 | Substituted chroman derivatives, medicaments and use in therapy | Marshall Edwards, Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-8084628-B2 | Substituted chroman derivatives, medicaments and use in therapy | MARSHALL EDWARDS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20080306140-A1 | Isoflavonoid Dimers | NOVOGEN RESEARCH PTY LTD (AU) | 2008-12-11 | — | — | US | disclosed |
| US-20080306140-A1 | Isoflavonoid Dimers | NOVOGEN RESEARCH PTY LTD (AU) | 2008-12-11 | — | — | US | disclosed |
| US-20080306140-A1 | Isoflavonoid Dimers | NOVOGEN RESEARCH PTY LTD (AU) | 2008-12-11 | — | — | US | disclosed |
| EP-1861402-A1 | ISOFLAVONOID DIMERS | Novogen Research Pty. Ltd. (AU) | 2007-12-05 | — | — | EP | disclosed |
| EP-1794141-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | Novogen Research Pty. Ltd. (AU) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006099681-A1 | ISOFLAVONOID DIMERS | NOVOGEN RESEARCH PTY LTD (AU) | 2006-09-28 | — | — | WO | disclosed |
| US-20060074127-A1 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | disclosed |
| WO-2006032085-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2006-03-30 | — | — | WO | disclosed |
| US-4814346-A | Benzopyrans and use thereof in treating vascular diseases | ZYMA SA (CH) | 1989-03-21 | — | — | US | disclosed |
| EP-0267155-A2 | Bicyclic compounds | Zyma SA (CH) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352074-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | MAPT 3391/4885RAB9A 3956/4885NPC1 2258/4885 |
| US-20140170243-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | MAPT 3391/4885RAB9A 3956/4885NPC1 2258/4885 |
| US-20120114766-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | MAPT 3391/4885RAB9A 3956/4885NPC1 2258/4885 |
| US-20060074127-A1 | anticancer agents; chemotherapeutic selective agents | MCL1, TOP2A, TP53 | MAPT 3789/4885RAB9A 1393/4885NPC1 1557/4885 |
| US-20160287555-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | CDYL, XPA, TP53 | MAPT 3391/4885RAB9A 3956/4885NPC1 2258/4885 |
| US-20080306140-A1 | Isoflavonoid Dimers | CDK2, CDK20, F2 | MAPT 2378/4885RAB9A 3410/4885NPC1 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.